Elekta (OTCMKTS:EKTAY) is a global medical technology company headquartered in Stockholm, Sweden, specializing in precision radiotherapy, radiosurgery and related software for the treatment of cancer and brain disorders. Through its research and development efforts, the company designs and manufactures advanced equipment and solutions that support clinicians in delivering targeted radiation treatments while minimizing damage to healthy tissue. Elekta’s offerings span hardware, software and services, addressing the full continuum of radiation oncology care.
Key products include linear accelerators for external beam radiation therapy, such as the Versa HD and Unity MR-linac systems, as well as Gamma Knife® platforms for stereotactic radiosurgery. The company also provides brachytherapy afterloaders and applicators for internal radiation treatments. Complementing its hardware portfolio, Elekta develops treatment planning and oncology informatics software that streamline workflow, enhance treatment accuracy and facilitate collaborative care across multidisciplinary teams.
Founded in 1972 by neurosurgeon Lars Leksell, Elekta has a long heritage in developing cutting-edge radiosurgery techniques and equipment. Over the decades, the company has pioneered innovations such as stereotactic radiosurgery and intensity-modulated radiation therapy, contributing to advances in patient outcomes and treatment precision. Elekta’s commitment to research is evidenced by partnerships with leading academic and clinical institutions worldwide.
Today, Elekta serves healthcare providers in more than 120 countries through a network of direct operations and authorized distributors. The company’s leadership team, headed by President and Chief Executive Officer Gustaf Salford, emphasizes strategic investments in technology, training and support services to ensure customers can maximize the value of their treatment platforms. By combining scientific expertise with global reach, Elekta continues to shape the future of radiation therapy and improve quality of life for patients around the world.
